+ T cell epitopes have been defined for any VZV protein. CD8 + T cell frequencies were assessed by cytokine flow cytometry (CFC), by use of synthetic-peptide pools corresponding to the IE62 sequence. IE62 peptide-specific CD8 + T cells were below the threshold of detection, by direct CFC of either whole blood or peripheral blood mononuclear cells (PBMCs). Activated CD8 + CD69 + T cells that produced interferon-g were detectable after in vitro restimulation of PBMCs, and restricted epitopes were identified for HLA-A*0201-positive subjects. Varicella vaccination of 3 VZV-immune subjects was associated with increases in IE62 peptide-specific CD8 + T cells, a finding indicating that in vivo re-exposure boosts memory immunity to this important viral protein.
mary VZV infection and the establishment of latency [2, 3] . VZV infection elicits IgM and IgG antibodies against many viral proteins, antibodies that can neutralize infectious virus [1, 2] . Natural killer cells may also contribute to the lysis of VZV-infected cells [4] [5] [6] . However, adaptive VZV-specific memory T cell responses appear to be necessary for both resolution of acute infection and, during latency, preservation of the balance between the virus and the host. VZV-specific CD4 + T cells both synthesize Th1-like cytokines, such as interleukin-2 and interferon (IFN)-g [7, 8] , and exhibit major histocompatibility complex (MHC) class II-restricted cyotoxicity [2, [9] [10] [11] . CD8 + T cell-mediated cytotoxicity has been documented by use of both highly purified subpopulations of CD8 + T cells, as effectors against lymphoblastoid cells expressing VZV proteins, and VZV-infected fibroblasts that express only MHC class I antigen as targets [10, 12] . The VZV genome consists of у70 unique open-reading frames (ORFs) that encode proteins that may be targets of adaptive immunity [1, 13, 14] . ORF62 en-codes the immediate early 62 (IE62), which is the major viraltransactivating protein required for initiation of VZV replication [14, 15] . In addition to its regulatory functions, IE62, which is an abundant component of the tegument, functions as a virion structural protein. Because of its location in the tegument, IE62 is released into the cellular cytoplasm at viral entry and uncoating; IE62 is an efficient activator of its own transcription in infected cells, where, during the initial phase of VZV replication, it is expressed at high levels and is exported from the nucleus to the cytosol [15] . In previous experiments, which used vaccinia recombinants, cytotoxic T lymphocytes (CTLs) that recognized IE62 were detected in CD4 + and CD8 + T cell subpopulations after primary VZV infection [10, 16] . Memory CTLs also recognize other structural/regulatory proteins of VZV, such as the IE63 protein, the ORF4 and ORF10 proteins [17, 18] , and viral glycoproteins, including gB, gC, gE, and gI [5, [9] [10] [11] 16] . However, because VZV replication interferes with the trafficking of MHC class I from the Golgi to the cell surface [19] , IE62 in may be a particularly important target of adaptive CD8 + T cell-mediated immunity, because IE62 is accessible for MHC class I presentation before viral replication has occurred. Memory T cells that recognize IE62 persist for decades after primary VZV infection and have been detected consistently in naturally immune individuals, as well as in individuals with immunity elicited by the live attenuated varicella vaccine [9, 10, 16, 17] .
Flow cytometry-based techniques in which T cell surface phenotypes and intracellular cytokine production are assessed simultaneously, have improved the quantitation of virus-specific CD4
+ and CD8 + memory T cells [20] [21] [22] [23] [24] [25] [26] . In a recent study, we used an intracellular cytokine flow cytometry (CFC) assay to compare the frequencies, in immune adults, of CD4 + and CD8 + memory T cells specific for the following: VZV, herpes simplex virus (HSV), and human cytomegalovirus (hCMV) [27] . The mean percentages of CD4 + CD69 + IFN-g + T cells detected after peripheral blood specimens had been incubated with unfractionated viral antigen preparations for 6 h were 0.11% for VZV, 0.22% for HSV, and 1.21% for hCMV. The expression of CD69 is used in combination with IFN-g, since CD69 is an early activation marker, which indicates recent restimulation. Under these conditions, whereas the mean frequency of hCMV-stimulated CD8 + T cells that produced IFNg was 1.1%, VZV-and HSV-specific CD8 + T cells were below the threshold of detection [27] .
After incubation with peptide pools (PPs) corresponding to the hCMV pp65 protein, hCMV-specific CD8 + T cells can be detected by CFC [20, 21, 23, 26] . To further assess the adaptive CD8 + T cell response to VZV, we used pools of synthetic peptides corresponding to overlapping residues of IE62. IE62 peptides were evaluated for their abilities to stimulate T cells, in either whole blood specimens or PBMCs, from VZV-immune individuals, by use of both direct CFC and CFC, after secondary in vitro stimulation by the peptides. The frequency of activated, IFN-g-producing CD8
+ T cells detected in response to IE62 peptides was determined by comparison with a panel of control peptides in VZV-immune subjects who were identified as either HLA-A*0201 positive or HLA-A*0201 negative. CD8 + T cell responses were also evaluated by use of IE62 PPs, after in vivo re-exposure to VZV by immunization, by administration of live attenuated varicella vaccine, of immune individuals. IE62 PPs may be useful for the assessment, in individuals with natural immunity and individuals with vaccine-induced immunity, of levels of CD8 + T cell-mediated immunity to VZV, as well as for the assessment of immunologic correlates of protection against primary and recurrent VZV infections.
SUBJECTS, MATERIALS, AND METHODS

Subjects.
The study population consisted of 13 healthy subjects with serum IgG antibodies to VZV (age range, 18-56 years); all subjects had a history of primary VZV infection during childhood; an additional subject had had acute varicella 3 weeks before initial evaluation. Three of these naturally immune subjects were tested for CD8 + T cell responses to IE62 peptides, both before and after booster immunization by live attenuated varicella vaccine (Varivax; Merck); the vaccine was administered as a 2-dose regimen, with doses separated by a 4-week interval. Informed consent was obtained from study participants, according to the U.S. Department of Health and Human Services and Stanford University guidelines for research involving human subjects.
Synthetic peptides. Synthetic 12-mer peptides overlapping by 6 aa were produced to correspond to the complete IE62, as determined from the consensus DNA sequence of ORF62 in the Dumas and Oka strains of VZV. VZV genome-sequence comparisons of these and other VZV strains are available at http://cmgm.stanford.edu/˜jjones/. Peptide 1 corresponded to IE62 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] , and peptide 2 corresponded to IE62 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , through the complete IE62 sequence. A total of 233 IE62 peptides were synthesized. When there was a predicted amino acid difference between the Oka and Dumas ORF62 sequences, a second peptide was produced, resulting in an additional 12 peptides. In addition, because of difficulties with synthesis or solubility of some peptides, the shift, in a few instances, was 5, 7, or 8 amino acids. Peptides were synthesized, by 9-fluorenylmethoxycarbonyl chemistry, on an MPS 350 multiple-peptide synthesizer (Advanced Chemtech), according to the manufacturer's protocols [28] . The peptides were tested by amino-acid analysis, high-performance liquid chromatography, and capillary electrophoresis and were further characterized by enzyme immunoassay against VZV-positive and VZV-negative serum samples. The single peptides were dissolved, at 25 mg/mL, in DMSO (Sigma) and were stored at Ϫ80ЊC. A synthetic peptide cor-responding to residues of the transferrin receptor was used as a control [27] ; this peptide was dissolved, at 1 mg/mL, in DMSO and was stored at Ϫ80ЊC. Single IE62 peptides were combined to prepare 32 PPs, each of which contained 15 peptides (final concentration, 1 mg peptide/mL, in DMSO). The PPs were designed so that each peptide was included in 2 PPs; PPs were aliquoted and were stored at Ϫ80ЊC.
Direct CFC assay. Either PPs (2 mg/mL/peptide) or controls-which included PBS (20 mL), staphylococcus enterotoxin B (SEB) (10 mg/mL) (Sigma), VZV-infected cell lysate (80 mL), uninfected cell lysate (80 mL) (BioWhittaker), and transferrin peptide (2 mg/mL)-were added to either heparinized whole blood (1 mL) or PBMCs ( cells/specimen). PBMCs 6 2.0 ϫ 10 were separated by Ficoll-Paque density centrifugation and were resuspended, to 1 mL, in RPMI 1640 (Gibco-BRL Life Technologies) containing 10% fetal bovine serum (FBS) (Gemini Bio-Products) and antibiotics, in 15-mL conical polypropylene tubes [25, 27] . Costimulatory monoclonal antibodies (mAbs)-CD28 and CD49d mAbs (final concentration, 3 mg/mL) (BD Immunocytometry Systems)-were added to each specimen except the PBS control. Costimulation by CD28 and CD49d does not activate T cells unless the latter are also stimulated by a specific antigen [26] . Tubes were vortexed and were incubated, for 6 h at 37ЊC, in 5% CO 2 . For the final 4 h, brefeldin A (10 mg/mL) was added. After the addition of ice-cold EDTA (final concentration, 2 mmol/L ), the tubes were vortexed for 10 s, were incubated for 15 min at room temperature, and were again vortexed for 10 s, before FACS Lysing Solution (13 mL/ tube) (BD Immunocytometry Systems) was added. The tubes were incubated for 10 min at room temperature and were stored at Ϫ80ЊC. Secondary in vitro stimulation by VZV peptides. PBMCs were isolated by Ficoll-Paque density gradient; PBMCs ( cells/specimen) were incubated in either RPMI 1640 6 2.0 ϫ 10 (1 mL) containing 10% FBS, antibiotics, and VZV peptides or in controls-which included PBS, SEB, VZV-infected cell lysate, uninfected cell lysate, or transferrin peptide-at 37ЊC, in 5% CO 2 . After 8 days, the cells were harvested from each well and were centrifuged at 500 g for 5 min at room temperature; supernatant was aspirated, and the pellet was resuspended in RPMI 1640 (200 mL) containing both 10% FBS and antibiotics. Restimulation mix containing either the VZV test peptides or the controls was added with CD28 and CD49d mAbs (final concentration, 3 mg/mL), at a final volume of 200 mL. The tubes were vortexed and were incubated, for 1 h at 37ЊC, in 5% CO 2 ; and RPMI 1640 (1600 mL) containing 10% FBS, antibiotics, and 4 mL brefeldin A (5 mg/mL) was added. After 5 h, 200 mL of an ice-cold solution of EDTA (20 mmol/L) was added, and the tubes were vortexed for 10 s, were incubated for 15 min at room temperature, and were again vortexed for 10 s. FACS Lysing Solution (4 mL) was added to each tube, and specimens were incubated for 10 min at room temperature and were stored at Ϫ80ЊC. HLA-A*0201 phenotype screening. After erythrocyte lysis of whole blood (1 mL), by addition of FACS Lysing Solution,the cells were stained by (1) either primary mAb MA2.1 (against HLA A2 and B17) or mAb BB7.2 (against HLA A2 and Aw69) (both clones were obtained from the American Type Culture Collection) and secondary fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (2.5 mg) (Pharmingen) or (2) both isotype control FITC-IgG1 and FITC-IgG3 (Caltag). The cells were fixed in FACS Fixative (1% formaldehyde in PBS) and were stored for р24 h at 4ЊC.
Flow-cytometric analysis. Stored samples were thawed rapidly and were centrifuged at 500 g for 5 min at room temperature, and supernatants were decanted. Cells were resuspended in fluorescence-activated cell sorter (FACS) buffer (3 mL), were aliquoted into 5-mL polystyrene tubes, and were centrifuged, and supernatant was decanted. FACS Permeabilizing Solution 2 (500 mL) (BD Immunocytometry Systems) was added, and tubes were vortexed. After incubation for 10 min at room temperature, FACS buffer (3 mL) was added, tubes were centrifuged, and supernatants were decanted. The mAbs used for staining were added to the residual volume, for 30 min at room temperature, in the dark. In most experiments, samples were stained by FITC-conjugated anti-IFN-g, peridinin chlorophyll protein (PerCP)-conjugated or PerCP-Cy5.5-conjugated anti-CD4 + , both PerCP-conjugated anti-CD8 + and allophyocyanin (APC) conjugated anti-CD3 mAbs (BD Immunocytometry Systems), phosphatidylethanolamine-conjugated anti-CD69 (Pharmingen), or FITC-conjugated IgG2b isotype control (Caltag). The cells were washed by FACS buffer and were centrifuged, and supernatant was decanted, before being fixed in FACS Fixative (100 mL) and stored at 4ЊC.
Stained samples were analyzed on a FACSCalibur flow cytometer (BD Immunocytometry Systems); 50,000-100,000 events/ sample were collected by gating on CD3 + T cells, by use of both forward-versus-side-light scatter technique and CD3 APC-versus-side-light scatter technique. PBS and isotype samples were used as a reference for gating. Further gating on CD4 .com) [29] . Every amino acid, at its position within a putative peptide, is evaluated with regard to anchor positions, auxiliary anchors, and preferred and disadvantageous amino acids. In combination with the binding predictions, the putative epitopes are evaluated for the potential of proteosomal cleavage, to limit the number of positive hits.
RESULTS
Direct CFC using IE62 PPs. In these experiments, 7 wholeblood specimens and 5 PBMC specimens, from VZV-immune subjects, were stimulated by PPsl 1, 2, 4, 7, 11, 12, and 15 and by positive and negative controls, for 6 h, and were analyzed for CD8 + CD69 + and intracellular IFN-g production, by flow cytometry (table 1) . In a representative experiment using whole blood (in a second evaluation of subject 4), the frequency of IE62 peptide-stimulated, activated CD8 + CD69
+ cells that were IFN-g positive ranged from 0 to 0.03% (figure 1); these frequencies are comparable to those for T cell activation and IFNg detection, in specimens incubated with negative controls, which ranged from 0 to 0.02%. The general failure to detect a CD8 + T cell response to IE62 PPs, under conditions of direct 6-h stimulation, as compared to detection of such a response in the controls, was confirmed in 7 subjects (table 1) . Overall, no difference in sensitivity of detection of IE62-peptide responses was detected by use of whole blood versus separated PBMCs, although, in the whole-blood assay, subjects 8 and 9 responded to PP 1 and/or PP 2. In addition, CD8 + T cells were not activated when the PP concentration was varied from 1 mg/mL to 10 mg/mL (data not shown). Incubation with VZVinfected cell lysate did not elicit detectable CD8 + T cell responses, a finding that confirms our earlier experiments [27] , whereas the SEB control showed that the CD8 + T cells could be activated in specimens from all subjects (range, 1.30%-14.40%).
CFC assay after secondary in vitro stimulation by IE62 PPs. In previous experiments performed by use of a limitingdilution cytotoxicity assay, the detection of IE62-specific CTLs required secondary in vitro exposure of CD8 + T cells to VZV [10] . Because CD8 + T cells were not detectable in the direct-CFC assay, gradient-separated PBMCs were stimulated, by either IE62 PPs or controls, for 8 days and were restimulated by the same PP, for 6 h, before FACS analysis. After 8 days of stimulation by PPs, CD8 + T cells that produced IFN-g were detected in both HLA-A*0201-positive subjects and HLA-A*0201-negative subjects, but not in controls, by use of PBMC specimens from 5 of 6 VZV-immune subjects (table 2) . Among these 5 subjects, activation of CD8 + T cells was detected in response to secondary stimulation by у1 of the IE62 PPs that were tested (day 8), compared to results obtained from the same subject under direct CFC conditions (day 0). The frequencies of activated CD8 + T cells increased from background levels (day 0) observed in the direct CFC assay to detectable responses at day 8 after the secondary in vitro stimulation and when compared to responses in negative controls tested under the conditions of the secondary in vitro stimulation assay.
Identification of IE62 PPs immunogenic in HLA-A*0201-positive subjects. Two HLA-A*0201-positive subjects (subjects 1 and 2) were evaluated, by use of PBMCs that had undergone secondary in vitro stimulation, in initial experiments for CD8 + T cell responses to IE62 PPs. CD8 + CD69 + T cells were detected in subject 1 in response to PPs 5 (aa 385-486) and 12 (aa 1032-1134), at frequencies of 0.09% and 0.11%, respectively, whereas CD8 + T cells were detected in subject 2 in response to PPs 5 and 10 (aa 853-954), at frequencies of 0.30% and 0.08%, respectively. As shown in figure 2A , when PBMCs from these 2 subjects were retested by use of PP 5, the detection of CD8 + CD69 + IFN-g + T cells was confirmed, and a third HLA-A*0201-positive subject (subject 3) also had a response to PP 5 ( figure 2A) . Stimulation of CD8 + T cells by PP 5 was detected in 2 additional HLA-A*0201-positive subjects (table 3) . In contrast, PP 5 did not activate CD8 + T cells from 4 HLA-A*0201-negative subjects but did do so in controls (table 3) ; results of evaluation of 1 HLA-A*0201-negative subject (subject 9) are shown in figure 2A .
Identification of single IE62 peptides immunogenic in HLA-A*0201-positive subjects.
The SYFPHETI algorithm was used to predict potential HLA-A*0201 epitopes within the amino acid sequences of peptides composing PP 5 (aa 385-486). The search was performed for nonamers and decamers, since amino acids of either length can bind to HLA-A*0201 molecules. Table 4 shows the 7 nonamer and 7 decamer epitopes that were scored highest, by the algorithm, in relation to the corresponding peptides within PP 5. On the basis of these predictions, epitopes within the peptides designated "P75," "P76," and "P79" were among those predicted to activate CD8 + T cells from HLA-A*0201-positive subjects. All of the single peptides that were present in PP 5, including P65-P80, were tested separately by use of PBMCs from subject 2, who was HLA-A*0201 positive. In this subject, as shown in figure 2B , only P75 and P79 induced activation of CD8 + T cells, as detected by CD69 and IFN-g expression, at frequencies of 0.32% and 0.10%, respectively. When the same experiment was performed by use of PBMCs from 4 more HLA-A*0201-positive subjects, responses to P75 and P79, but not to other peptides in PP 5, were detected (table 5). Responses to the complete 2 ϫ 10 days, and were restimulated by either PP 5 or single peptides, and CD28 and CD49d, for 6 h; brefeldin A was added during the final 5 h. The cells were stained by anti-interferon (IFN)-g-fluorescein isothiocyanate (FITC), CD69-phosphatidylethanolamine (PE), CD8-peridinin chlorophyll protein, and CD3-allophyocyanin and were analyzed by flow cytometry.
PP 5 were confirmed, in parallel, in all of these HLA-A*0201-positive subjects (table 5) . In contrast, CD8 + T cells from 3 HLA-A*0201-negative subjects were not stimulated by any single peptide from P65-P80 or by the complete PP 5 (table 5). All HLA-A*0201-positive subjects had CD8 + T cells that recognized both P75 and P79, but the CD8 + T cell frequencies for each peptide varied among individual subjects; for example, P79 was relatively immunodominant in subjects 1 and 3, whereas subject 2 had more CD8 + T cells that recognized P75. CD8 + T cell responses to PPs in a subject with primary VZV infection. Subject 11, who was HLA-A*0201 negative, was evaluated 3 weeks after onset of primary VZV infection. Under direct-CFC conditions, no activated CD8 + T cells were detected in response to stimulation of PBMCs by any of the PPs (data not shown). In parallel experiments, in which PBMCs from subject 11 were stimulated by PPs for 8 days and were then restimulated for 6 h, CD8 + T cell activation and IFN-g production was detected in response to PPs 7, 11, and 15 (figure 3), at frequencies of 5.58%, 0.42%, and 1.22%, respectively. The remaining PPs did not elicit T cell activation; frequencies of CD8 + CD69 + IFN-g + T cells observed after stimulation by these PPs ranged from 0.01% to 0.07% and were comparable to those observed after in vitro stimulation by controls.
Kinetics of CD8 + T cell responses to PPs after immunization by live attenuated varicella vaccine. After immunization by live attenuated varicella vaccine, subject 1's CD8 + T cell responses to PPs were further investigated. This subject had been tested repeatedly before vaccination, as shown in tables 1-3 and 5. In the experiments shown in figure 4, PBMCs were collected just before vaccine was administered and 7, 14, and 28 days later; a second dose of vaccine was administered 28 days after PBMCs were collected, and subsequent specimens were collected 35, 42, and 56 days after the first vaccine dose (i.e., 7, 14, and 28 days after the second dose) (figure 4A). In subject 1, an increase in the CD8 + T cell response to PP 5 was detected by 14 days after the first dose, and this increase persisted through 42 days after the first dose. None of the other PPs induced a detectable CD8 + T cell response at any time after the first or second dose, as illustrated for PP 9 (figure 4A). These results, which were consistent with our previous investigations of this HLA-A*0201-positive subject, showed that, for this subject, PP 5 contained the immunodominant peptides P75 and P79, since the boost in response to PP 5 was documented after in vivo exposure to VZV by the live attenuated vaccine. An increase in the CD8 + T cell response to PP 5 was observed in a second HLA-A*0201-positive subject (subject 18) after the first dose of vaccine; this response declined by 28 days after PBMCs were collected but was boosted after the second dose ( figure 4B ). Subject 18 also developed a response to PP 4 after the first dose of vaccine; this response had not been detectable at baseline (day 0) but was boosted after the second dose ( figure 4B ). This observation suggests that in vivo exposure to VZV could reveal memory CD8 + T cells specific for another IE62 peptide, although a single-peptide analysis of PP 4 peptides was not performed. As expected, when similar kinetics experiments were performed on subject 17, who was HLA-A*0201 negative, no response to PP 5 was detected at any time. However, subject 17 had evidence of enhanced responses to peptides in PPs 12, 14, and 15, after the first and second doses of vaccine ( figure 4C ). All PPs were tested at each of 7 times, in all 3 subjects; no variation above background was observed when any of the PPs were used, except as shown in figure 4.
DISCUSSION
Stimulation, by synthetic peptides, of PBMCs from VZV-immune individuals in conjunction with evaluation, by CFC, for T cell activation and IFN-g production, permitted the detection of CD8 + T cells that recognize VZV IE62. By use of pooled IE62 peptides, immunogenic epitopes within IE62, which is the major regulatory/structural protein of VZV, were identified in PBMCs from both HLA-A*0201-positive subjects and HLA-A*0201-negative subjects. Detection of IE62-specific CD8 + T cells required short-term in vitro expansion by peptides, a finding indicating that these cells were not maintained at measurable frequencies in the circulating memory CD8 + T cell pool. The IE62-peptide CFC assay has allowed us to document that varicella vaccination increases the frequency of IE62-specific CD8 + T cells in healthy VZV-immune subjects. This observation shows that populations of VZV-specific memory CD8 + T cells could be expanded by vaccination and supports the idea that varicella vaccination may be useful as a way to reverse declining memory immunity to VZV, which is associated with herpes zoster in elderly persons [30] .
CFC assays that measure both T cell activation and IFN-g production have been used to assess the frequencies of human memory CD4 + and CD8 + T cells against several viral pathogens [20] [21] [22] [23] [24] [25] [26] [27] [31] [32] [33] [34] . VZV antigen, consisting of a VZV-infected cell lysate, can be used to quantitate, under standard CFC assay conditions, memory CD4 + T cells that recognize VZV proteins, on the basis of production of IFN-g or tumor necrosis factor-a, but antigen-specific activation of CD8 + T cells is not detected by this antigen preparation, when either cytokine is used as the marker of memory antiviral CD8 + T cells [27] . This observation can be attributed to the fact that exogenous antigens are poorly cross-presented by the MHC class I pathway [35] . Since crosspriming is inefficient, we have examined whether increasing the concentration of IE62 peptides in the synthetic PPs might result in CD8 + T cell stimulation. However, CD8 + T cell responses were not detected by use of IE62-peptide concentrations of 1-10 mg/mL; 10 mg/mL is the maximum peptide concentration that has been reported to be effective in CFC assays [35] . As expected, antigen-independent activation of CD8 + T cells by SEB was demonstrated in most subjects, a finding indicating that there was not a general-defect CD8 + T cell responsiveness. The results of direct CFC experiments using IE62 peptides indicate that our previously reported failure to detect VZV-specific CD8 + T cells by use of unfractionated VZV-infected cell lysate was not simply a consequence of inefficient processing of exogenous antigen for peptide-MHC class I complex formation [27] .
The standard intracellular cytokine assay is designed to detect cytokine-secreting cells that are activated, without any proliferation of antigen-specific memory T cells, for only a few hours after antigen stimulation [24] [25] [26] . Since these conditions did not demonstrate the presence of memory T cells that recognized IE62 peptides, we investigated whether VZV-specific memory CD8 + T cells could be detected after PBMCs were stimulated by PPs for 8 days. Under these conditions, which permit antigen-specific T cells to undergo some clonal expansion, CD8 + CD69 + IFN-g + T cells were identified in PBMC specimens, by CFC assays using either the same PP or the individual IE62 peptide. Whereas no responses to direct stimulation were detected, the percentages of CD8 + T cells in PBMCs from the same subjects that, after secondary in vitro stimulation, recognized IE62 PPs ranged from 0.12% to 2.75% (table 2) . HLA-A*0201-positive subjects had responses to P75 (aa 45-453) and + T cell responses to IE62 peptides were evaluated in 3 subjects (subjects 1, 17, and 18) at baseline and at intervals after the administration of each of 2 doses of vaccine (arrows on the horizontal axis indicate vaccine administration). At each interval (indicated on the horizontal axis), peripheral blood mononuclear cells ( cells/specimen) were stimulated ex vivo 6 2 ϫ 10 by PPs 1-15 (2 mg/mL) for 8 days. The cells were restimulated by the PPs (10 mg/mL) with costimulatory monoclonal antibodies, for 6 h; brefeldin A (10 mg/mL) was added for the final 5 h. The cells were stained by anti-interferon (IFN)-g-fluorescein isothiocyanate, CD69-phosphatidylethanolamine, CD8-peridinin chlorophyll protein, and CD3-allophyocyanin and were analyzed by flow cytometry. Responses to PPs 5 and 9 were detected in subject 1 and to PPs 4 and 5 in subject 18, both of whom were HLA-A*0201 positive; no responses to the other PPs, above baseline, were detected after in vivo re-exposure by varicella vaccination. Subject 17 was HLA-A*0201 negative and did not respond to PP 5 but did have increased CD8 + T cell frequencies in response to PPs 12, 14, and 15, after varicella vaccination. The broken lines indicate the mean CD8 + T cell frequencies for PPs that did not elicit responses above controls, for each subject, over the study period.
P79 (aa 472-480); these regions of the IE62 amino acid sequence do not vary in VZV strains that have been reported to GenBank. Whereas these regions are involved in IE62-transactivating functions, there is no predicted relationship between amino acid residues that are important for the viral regulatory functions of IE62 and those that might be recognized by memory CD8 + T cells. Also, VZV-specific memory cytotoxic T cells have not been detected in PBMCs from immune subjects who have not received secondary in vitro stimulation [3, [8] [9] [10] [11] [12] . Under limiting-dilution conditions with short-term expansion, by use of autologous targets infected by VZV-IE62 vaccinia recombinants, the mean frequency of cytotoxic CD8 + T cells specific for IE62 was 1:74,000 [10] . Thus, the responder-cell frequencies of memory CD8 + T cells specific for IE62 peptides (frequencies estimated at 1:20,000-1:50,000) , detected by CFC after short-term in vitro expansion were comparable to those detected by limiting-dilution cytotoxicity assays using purified CD8 + T cell populations from VZV-immune subjects. In 1 healthy individual, we have had the opportunity to evaluate CD8 + T cell responses to PPs 3 weeks after the occurrence of primary VZV infection. In this subject, IE62 peptide-specific CD8 + T cell frequencies were !3-fold higher than those for controls, although the response to PP 4 was 0.11%, which approached the threshold of detection under conditions of direct assays using whole blood (table 1). The kinetics of the CD8 + T cell response to VZV may consist of an early expansion during acute varicella, an expansion that resolves to low levels of memory CD8 + T cells when viremia and replication in skin lesions have been cleared and VZV latency in sensory ganglia has been established [2] . Vaccination, by live attenuated varicella vaccine, of VZV-immune individuals who had primary VZV infection during childhood was associated with a subsequent increase in the frequencies of IE62 peptide-specific CD8 + T cells in PBMC specimens. These experiments indicate that it is possible to enhance memory CD8 + T cell responses by use of live attenuated varicella vaccine, as has been demonstrated for VZV-specific CD4 + T cell responses [30] . Whether these transient increases in the percentages of CD8 + T cells that recognize IE62 peptides might contribute to vaccine-induced protection against herpes zoster-a protection resulting from the reactivation of latent VZV-is not known.
VZV, like hCMV, causes persistent infection in a healthy host, but the site of VZV persistence is within neuronal cells, whereas hCMV is maintained within circulating myeloid progenitor cells [36] . Cytotoxic T cells that recognize hCMV proteins have been demonstrated to circulate at very high frequencies in hCMV-seropositive individuals [37] and can be detected readily by the standard CFC assay [20] [21] [22] [23] [24] [25] [26] . Dunn et al. reported that 0.1%-15.0% of CD8 + T cells from hCMV-immune individuals were activated by pp65 peptides [20] . Kern et al. found that hCMV-seropositive subjects had a mean CD8 + T cell frequency of 5.46% cells specific for IE1 peptides, in addition to a mean CD8 + T cell frequency of 4.33% cells specific for pp65 peptides [21] . Individuals who are chronically infected by human immunodeficiency virus or hepatitis C virus may have even higher frequencies of virus-specific CD8 + T cells, depending on their disease status [31, 33, 37] . These patterns indicate that viral pathogens that either continue to replicate after primary infection or reactivate frequently are likely to induce and maintain high numbers of memory CD8 + T cells in the population of circulating CD8 + T cells. Our observations suggest that comparable numbers of circulating virus-specific CD8 + T cells are not required for immune surveillance against viral pathogens, such as VZV, which persists in neurons, an immunologically "privileged" site, and reactivates relatively rarely during the lifetime of the host [1] . Nevertheless, CD8
+ T cells that recognize IE62, which is critical for VZV replication, are present in immune individuals, and, on re-exposure to IE62 peptides, these populations of CD8 + T cells can be expanded.
